Jowin plans to establish a telemedicine platform for overseas patients with stage 4 and terminal cancer and launch it in the first half of this year.
Collaboration with licensed traditional Korean medicine doctors and fostering ‘cansultants,’ counselors specializing in cancer patients, for Jowin’s global telemedicine services.
Will employ ‘cansultants’ and ‘traditional medicine doctors’ in February… and train them for the telemedicine platform to provide patients non-face-to-face medical services
Jowin (CEO Yoo Yeon-jeong) sets this year as their first year of entering the global cancer care market and will establish a global telemedicine platform that provides high-quality medical services to patients with stage 4 and terminal cancer.
Jowin plans to launch a telemedicine platform that can be accessed via mobile phone applications (apps) and online (web) in the first half of the year to help treat overseas cancer patients who want to experience Korea's advanced medical system but have difficulty entering the country due to time, cost, and/or physical distance. The telemedicine platform, which will be developed in two versions, Korean and English, will gradually expand its market scope to the United States, China, and Europe after its first launch in Korea and Southeast Asian countries.
Jowin’s telemedicine platform is to be available to cancer patients and their guardians in Korea and abroad. When the basic personal information and condition of a cancer patient is registered on the app and website, a “cansultant,” a counselor specializing in cancer patients at Jowin, reviews the patient's past medical history and provides them a consultation service around the patient’s current psychological status and so on. Afterwards, a traditional Korean medicine doctor who has completed the cancer treatment training from Jowin's advisory committee of cancer specialists gives the patient a customized prescription following a non-face-to-face medical examination. Along with the physical suffering cancer patients experience, emotional distress is another battle they endure. In consideration of this, Jowin plans to also strive to provide psychological treatment by cansultants to patients for areas including fear of death, anxiety, and concerns about recurrence.
Based on the prescription from a traditional Korean medicine doctor through the telemedicine platform, Jowin will provide a total solution package that includes ‘UNBIJE’, a natural anti-cancer drug, ‘HiB&D’, a nutritional supplement exclusively for cancer patients, a protein supplement for the nutritional balance of cancer patients, and 'body temperature-raising medicinal water' approved by the U.S. Food and Drug Administration (FDA). UNBIJE is a non-toxic herbal medicine developed by Jowin, made of the natural mineral 'sericite', that has been showing efficacy and the ingredient has been subjected to clinical trials for several years. The mechanism of its cancer treatment efficacy were published in ‘Hindawi’, the internationally renowned SCI-grade journal covering the field of alternative medicine, in October of last year.
Prior to the launch of the global telemedicine platform, Jowin will be recruiting for the month of February for licensed traditional Korean medicine doctors and cansultants to collaborate on the platform. Traditional Korean medicine license holders and cansultants can apply on the Jowin website, and the recruitment, selection, and training for overseas applicants will be conducted through 'HL Group', the local partner in Bangladesh, which has signed a business agreement with Jowin last year.
After the final confirmation of collaboration, the traditional Korean medicine doctors and cansultants will officially start providing telemedicine services after receiving training through Jowin’s cancer treatment and counseling curriculum. The common curriculum comprises three courses which are psychotherapy, basic understanding of cancer, and dietary strategy, and the traditional Korean medicine doctors will receive guidance in the treatment and prescription for cancer patients while the cansultants learn about the company and its product, and also study psychological counseling.
CEO Yoo Yeon-jeong, a doctor of medicine, said, “Jowin’s entry into the global market won’t be that difficult since most countries have an expanded access program, a system that allows the prescription of investigational drugs upon consent of the doctors, patients, and guardians, for the treatment for terminal cancer. Also, there won’t great difficulty in exporting UNBIJE since it is included in the same category as edible minerals, herbs, and herbal medicine.“ She added, “We plan to combine Jowin’s total cancer treatment solution with K-Medi, which has recently been in the limelight in the overseas market, and supply it to the global market through active business agreements with local companies with high regional sentiment and understanding, following our partnership with HL Group.”
Meanwhile, Jowin is working towards a holistic cancer treatment that not only fights cancer and increases the survival rate of cancer patients but also improves their quality of life and mindfulness. Last year, Jowin also held an online live ZOOM lecture for cancer patients. In addition, the company is working closely with related companies to develop a digital cancer treatment by systematizing the data collection of cancer patients based on the accumulated know-how and results. Jowin plans to form partnerships with cancer hospitals in Korea to conduct medical tours for patients with refractory and incurable cancer around the world in the future.
wiki@wikileaks-kr.org
